In line with these findings, Martincuks and colleagues [30] showed that PARPi treatment promotes STAT3 activation in ovarian cancer cells, tumor-associated immune cells and fibroblasts, resulting in PARPi resistance and immunosuppression. The gene discussed is STAT3; the disease is ovarian carcinoma.